ProMIS Neurosciences, Inc.

NASDAQ:PMN

Biotechnology

Healthcare
$11.08 -0.14%

-$0.02 today

Market cap
$99.36M
Beta
-0.22
P/E (TTM)
-0.6
EPS (TTM)
-$4.62
52W Low $6.27High $27.40

Volume 0.13M

Average 0.07M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$28.12M

FY 2025 · Annual

Investing Cash Flow

-$702.00

FY 2025 · Annual

Financing Cash Flow

$20.94M

FY 2025 · Annual

-24.9% YoY

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Net Income(9.4M)(24.27M)(13.21M)2.78M(39.72M)
Depreciation & Amortization46.46K15.07K21.16K00
Deferred Income Tax00000
Stock-Based Compensation0655.2K271.54K825.81K857.63K
Change in Working Capital(1.59M)7.26M2.94M(11.73M)10.75M
Accounts Receivables(17.57K)0000
Inventory00000
Accounts Payables(32.09K)3.6M4.96M(6.11M)805.95K
Other Working Capital(1.54M)3.66M(2.02M)(5.62M)9.94M
Other Non-Cash Items1.5M(6.55M)(868.56K)(19.06M)(5.59K)
Operating Cash Flow(9.44M)(22.89M)(10.84M)(27.18M)(28.12M)
Capital Expenditures(6.12K)(2.66K)000
Acquisitions (Net)99.7K0000
Purchases of Investments(33.56K)(41.67K)(32.36K)(33.05K)(33.75K)
Sales of Investments35.92K41.67K31.01K32.36K33.05K
Other Investing Activities00000
Investing Cash Flow95.93K(2.66K)(1.35K)(693)(702)
Debt Repayment00000
Common Stock Issued25.63M6.68M17.75M27.85M20.94M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities02.04M3.6K28.04K0
Financing Cash Flow25.63M8.73M17.75M27.88M20.94M
Effect of Forex Changes(114.46K)(707.96K)(181.43K)00
Net Change in Cash16.17M(14.87M)6.72M693.02K(7.17M)
Free Cash Flow(9.45M)(22.89M)(10.84M)(27.18M)(28.12M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$39.7M
+ D&A$0
+ Stock-Based Comp$857.6K
+ Deferred Tax$0
+ Working Capital$10.7M
- Other Non-Cash-$5.6K
= Operating Cash Flow-$28.1M
- Capex$0
= Free Cash Flow-$28.1M

Analysis

FY2025 free cash flow is -$28.1M. FCF conversion is 70.8% of net income. Operating cash flow was -$28.1M, with capex of $0. The largest bridge item is Working Capital at $10.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipOct 6, 2026
3Initial statement of beneficial ownershipOct 6, 2026
SC 13G/ASC 13G/A filingAug 14, 2026
SC 13G/ASC 13G/A filingAug 13, 2026
8-KCurrent reportAug 13, 2026

Does PMN generate free cash flow?

ProMIS Neurosciences, Inc. (PMN) generated -$28.12M of free cash flow in fiscal 2025.

How much operating cash flow does PMN produce?

Operating cash flow was -$28.12M, before capital expenditures of $0.00.